These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26369764)

  • 1. [Current concept for the microbiological safety of cell-based medicinal products].
    Schurig U; Karo JO; Sicker U; Spindler-Raffel E; Häckel L; Spreitzer I; Bekeredjian-Ding I
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1225-32. PubMed ID: 26369764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Specific aspects for virus safety of raw materials for cellular-based medicinal products].
    Stühler A; Blümel J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1233-8. PubMed ID: 26383536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycoplasma testing of cell substrates and biologics: Review of alternative non-microbiological techniques.
    Volokhov DV; Graham LJ; Brorson KA; Chizhikov VE
    Mol Cell Probes; 2011; 25(2-3):69-77. PubMed ID: 21232597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A validation protocol and evaluation algorithms to determine compatibility of cell therapy product matrices in microbiological testing.
    Klarmann D; Sireis W; Hogardt M; Kempf VA; Seifried E; Bonig H
    Cell Tissue Bank; 2015 Sep; 16(3):311-8. PubMed ID: 25204399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Problems in microbial safety of advanced therapy medicinal products. Squaring the circle].
    Montag-Lessing T; Störmer M; Schurig U; Brachert J; Bubenzer M; Sicker U; Beshir R; Spreitzer I; Löschner B; Bache C; Becker B; Schneider CK
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):45-51. PubMed ID: 20012926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Strategic considerations on the design and choice of animal models for non-clinical investigations of cell-based medicinal products].
    Lehmann J; Schulz RM; Sanzenbacher R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1215-24. PubMed ID: 26431722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety monitoring of cell-based medicinal products (CBMPs)].
    Funk MB; Frech M; Spranger R; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1239-46. PubMed ID: 26391098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk reduction in biotherapeutic products.
    Ill CR; Dehghani H
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):296-304. PubMed ID: 19333875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Viral safety of biological medicinal products].
    Stühler A; Blümel J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1198-202. PubMed ID: 25123140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The scope of mycoplasma contamination within the biopharmaceutical industry.
    Armstrong SE; Mariano JA; Lundin DJ
    Biologicals; 2010 Mar; 38(2):211-3. PubMed ID: 20362237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategy for an abbreviated in-house qualification of a commercially available Rapid Microbiology Method (RMM) for canadian regulatory approval.
    Chisholm J; Bhatt S; Chaboureau A; Viswanathan S
    Cytotherapy; 2017 Dec; 19(12):1529-1536. PubMed ID: 29066052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why and how to implement a rapid sterility test.
    Gressett G; Vanhaecke E; Moldenhauer J
    PDA J Pharm Sci Technol; 2008; 62(6):429-44. PubMed ID: 19634346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Assessment Approach to Microbiological Controls of Cell Therapies.
    Cundell T; Drummond S; Ford I; Reber D; Singer D;
    PDA J Pharm Sci Technol; 2020; 74(2):229-248. PubMed ID: 31941793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amendments to sterility test requirements for biological products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2012 May; 77(86):26162-75. PubMed ID: 22606719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbial safety of cell based medicinal products--what can we learn from cellular blood components?
    Montag T; Nicol SB; Schurig U; Heiden M; Huber H; Sanzenbacher R; Flory E; Schwanig M; Schneider CK
    Clin Chem Lab Med; 2008; 46(7):963-5. PubMed ID: 18624618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory and microbiological safety issues surrounding cell and tissue-engineering products.
    Galbraith DN
    Biotechnol Appl Biochem; 2004 Aug; 40(Pt 1):35-9. PubMed ID: 15270705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of growth based rapid microbiological methods for sterility testing of vaccines and other biological products.
    Parveen S; Kaur S; David SA; Kenney JL; McCormick WM; Gupta RK
    Vaccine; 2011 Oct; 29(45):8012-23. PubMed ID: 21871516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sterility testing of cell therapy products: parallel comparison of automated methods with a CFR-compliant method.
    Khuu HM; Patel N; Carter CS; Murray PR; Read EJ
    Transfusion; 2006 Dec; 46(12):2071-82. PubMed ID: 17176318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22-23 April 2009, Bethesda, USA.
    Knezevic I; Stacey G; Petricciani J; Sheets R;
    Biologicals; 2010 Jan; 38(1):162-9. PubMed ID: 19818645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
    Kozak RW; Golker CF; Stadler P
    Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.